SG11201907451XA - Substituted imidazo-quinolines as nlrp3 modulators - Google Patents

Substituted imidazo-quinolines as nlrp3 modulators

Info

Publication number
SG11201907451XA
SG11201907451XA SG11201907451XA SG11201907451XA SG11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA
Authority
SG
Singapore
Prior art keywords
princeton
route
line road
international
province line
Prior art date
Application number
SG11201907451XA
Other languages
English (en)
Inventor
Gary Glick
Shomir Ghosh
William R Roush
Edward James Olhava
Daniel O'malley
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61283434&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907451X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of SG11201907451XA publication Critical patent/SG11201907451XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Optical Communication System (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Transducers For Ultrasonic Waves (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201907451XA 2017-02-17 2018-02-16 Substituted imidazo-quinolines as nlrp3 modulators SG11201907451XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762460677P 2017-02-17 2017-02-17
US201762490881P 2017-04-27 2017-04-27
US201762573991P 2017-10-18 2017-10-18
PCT/US2018/018484 WO2018152396A1 (en) 2017-02-17 2018-02-16 Substituted imidazo-quinolines as nlrp3 modulators

Publications (1)

Publication Number Publication Date
SG11201907451XA true SG11201907451XA (en) 2019-09-27

Family

ID=61283434

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907451XA SG11201907451XA (en) 2017-02-17 2018-02-16 Substituted imidazo-quinolines as nlrp3 modulators

Country Status (29)

Country Link
US (4) US10533005B2 (hr)
EP (2) EP3510034B1 (hr)
JP (1) JP7003143B6 (hr)
KR (1) KR102329062B1 (hr)
CN (1) CN110325534B (hr)
AU (1) AU2018221076B2 (hr)
BR (1) BR112019016625A2 (hr)
CA (1) CA3053949A1 (hr)
CL (1) CL2019002324A1 (hr)
CO (1) CO2019008932A2 (hr)
CY (1) CY1123305T1 (hr)
DK (1) DK3510034T3 (hr)
ES (1) ES2799900T3 (hr)
HR (1) HRP20201087T1 (hr)
HU (1) HUE050965T2 (hr)
IL (1) IL268640B (hr)
LT (1) LT3510034T (hr)
ME (1) ME03801B (hr)
MX (1) MX2019009788A (hr)
MY (1) MY194054A (hr)
PE (1) PE20191552A1 (hr)
PL (1) PL3510034T3 (hr)
PT (1) PT3510034T (hr)
RS (1) RS60548B1 (hr)
SG (1) SG11201907451XA (hr)
SI (1) SI3510034T1 (hr)
TW (1) TWI674261B (hr)
WO (1) WO2018152396A1 (hr)
ZA (1) ZA201906104B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
PE20200296A1 (es) 2017-07-14 2020-02-06 Innate Tumor Immunity Inc Moduladores de nlrp3
CU24615B1 (es) 2017-07-24 2022-07-08 Novartis Ag Compuestos para tratar afecciones asociadas con la actividad nlrp
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP4006034A1 (en) 2017-10-18 2022-06-01 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
KR20210045430A (ko) * 2018-08-16 2021-04-26 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
CN112888677A (zh) 2018-08-16 2021-06-01 先天肿瘤免疫公司 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法
CN113038989A (zh) * 2018-08-16 2021-06-25 先天肿瘤免疫公司 咪唑并[4,5-c]喹啉衍生的nlrp3调节剂
CN111253390B (zh) * 2018-11-30 2023-10-03 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
CN113286787A (zh) * 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
WO2020150115A1 (en) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
EP3929185A4 (en) 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. CONDENSED CYCLIC COMPOUND CONTAINING NITROGEN, METHOD FOR PREPARATION AND USE
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
EP4076445A1 (en) * 2019-12-20 2022-10-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
KR102409345B1 (ko) * 2020-09-22 2022-06-16 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
CN116874340B (zh) * 2023-07-10 2024-04-05 湖北航天化学技术研究所 一种苯基***类含能共晶化合物及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US948029A (en) * 1909-04-23 1910-02-01 James Harvey Leffler Reclining-chair.
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
CZ285050B6 (cs) * 1991-03-01 1999-05-12 Minnesota Mining And Manufacturing Company 1-Substituované, 2-substituované-1H-imidazo/4,5-c /chinolin-4-aminy
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP2939693A1 (en) 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
AP2006003542A0 (en) 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007513170A (ja) 2003-12-04 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー スルホン置換イミダゾ環エーテル
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007530579A (ja) 2004-06-10 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
CN101056877B (zh) 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
EP1830880A4 (en) 2004-12-30 2008-03-26 Coley Pharm Group Inc MULTI-CHANNEL ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
CA2598656A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
US8436178B2 (en) 2007-05-08 2013-05-07 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
MX2015015037A (es) 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
AU2014268836B2 (en) 2013-05-18 2018-08-02 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
EA035037B1 (ru) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于***的抗-pd-l1结合物
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
JP6900323B2 (ja) 2015-05-29 2021-07-07 アジェナス インコーポレイテッド 抗ｃｔｌａ−４抗体およびその使用方法
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
US20170056448A1 (en) 2015-09-01 2017-03-02 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于***的抗-egfr组合
US10730871B2 (en) 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10556903B2 (en) * 2016-04-19 2020-02-11 Innate Tumor Immunity, Inc. NLRP3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑

Also Published As

Publication number Publication date
PT3510034T (pt) 2020-06-23
EP3753938A1 (en) 2020-12-23
HRP20201087T1 (hr) 2020-10-30
RS60548B1 (sr) 2020-08-31
US20200157096A1 (en) 2020-05-21
KR20190117657A (ko) 2019-10-16
ES2799900T3 (es) 2020-12-22
EP3510034A1 (en) 2019-07-17
LT3510034T (lt) 2020-08-10
KR102329062B1 (ko) 2021-11-18
DK3510034T3 (da) 2020-07-27
CY1123305T1 (el) 2021-12-31
WO2018152396A1 (en) 2018-08-23
PE20191552A1 (es) 2019-10-24
JP2020508302A (ja) 2020-03-19
AU2018221076A1 (en) 2019-10-03
US11827632B2 (en) 2023-11-28
CO2019008932A2 (es) 2020-01-17
IL268640B (en) 2021-12-01
EP3510034B1 (en) 2020-04-22
IL268640A (en) 2019-10-31
JP7003143B2 (ja) 2022-01-20
CN110325534B (zh) 2024-04-05
JP7003143B6 (ja) 2024-02-26
CN110325534A (zh) 2019-10-11
CA3053949A1 (en) 2018-08-23
NZ757257A (en) 2021-11-26
US10533005B2 (en) 2020-01-14
TW201835077A (zh) 2018-10-01
EP3753938B1 (en) 2024-03-20
HUE050965T2 (hu) 2021-01-28
MX2019009788A (es) 2019-10-07
ME03801B (me) 2021-04-20
PL3510034T3 (pl) 2020-11-30
US20190055236A1 (en) 2019-02-21
US20220289736A1 (en) 2022-09-15
AU2018221076B2 (en) 2020-12-24
SI3510034T1 (sl) 2020-11-30
TWI674261B (zh) 2019-10-11
BR112019016625A2 (pt) 2020-04-14
CL2019002324A1 (es) 2019-11-29
ZA201906104B (en) 2021-05-26
MY194054A (en) 2022-11-10
US20240067649A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201809082WA (en) Nlrp3 modulators
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201906465YA (en) Tigit- and light-based chimeric proteins
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201901937WA (en) Pyridine compound
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201907217RA (en) Pharmaceutical combinations for treating cancer